Literature DB >> 34958455

The Potential of Psychedelics for End of Life and Palliative Care.

David B Yaden1, Sandeep M Nayak2, Natalie Gukasyan2, Brian T Anderson3, Roland R Griffiths4.   

Abstract

End of life and palliative care has improved in recent decades but the psychopharmacological options available to clinicians and patients in these contexts remain limited. In particular, psychological factors such as depression, existential distress, and well-being remain challenging to address with current medications. Here, we review recent research on the use of psychedelics in clinical settings with a particular focus on patients with life-threatening diagnoses. We propose that psychedelics may provide clinicians with an additional psychopharmacological treatment in the context of end of life and palliative care.
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Entities:  

Keywords:  End of Life; Palliative care; Psilocybin; Psychedelics; Psychiatry

Mesh:

Substances:

Year:  2022        PMID: 34958455     DOI: 10.1007/7854_2021_278

Source DB:  PubMed          Journal:  Curr Top Behav Neurosci        ISSN: 1866-3370


  48 in total

1.  Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-10-06       Impact factor: 4.153

2.  Effects of existential interventions on spiritual, psychological, and physical well-being in adult patients with cancer: Systematic review and meta-analysis of randomized controlled trials.

Authors:  Natalie Bauereiß; Stefanie Obermaier; Selçuk Erol Özünal; Harald Baumeister
Journal:  Psychooncology       Date:  2018-08-02       Impact factor: 3.894

3.  Trial of Psilocybin versus Escitalopram for Depression.

Authors:  Robin Carhart-Harris; Bruna Giribaldi; Rosalind Watts; Michelle Baker-Jones; Ashleigh Murphy-Beiner; Roberta Murphy; Jonny Martell; Allan Blemings; David Erritzoe; David J Nutt
Journal:  N Engl J Med       Date:  2021-04-15       Impact factor: 91.245

4.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

5.  Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.

Authors:  Gabrielle I Agin-Liebes; Tara Malone; Matthew M Yalch; Sarah E Mennenga; K Linnae Ponté; Jeffrey Guss; Anthony P Bossis; Jim Grigsby; Stacy Fischer; Stephen Ross
Journal:  J Psychopharmacol       Date:  2020-01-09       Impact factor: 4.153

6.  The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients.

Authors:  E Bruera; N Kuehn; M J Miller; P Selmser; K Macmillan
Journal:  J Palliat Care       Date:  1991       Impact factor: 2.250

7.  Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.

Authors:  Brian T Anderson; Alicia Danforth; Prof Robert Daroff; Christopher Stauffer; Eve Ekman; Gabrielle Agin-Liebes; Alexander Trope; Matthew Tyler Boden; Prof James Dilley; Jennifer Mitchell; Joshua Woolley
Journal:  EClinicalMedicine       Date:  2020-09-24

8.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

9.  Training and career development in palliative care and end-of-life research: opportunities for development in the U.S.

Authors:  Noreen M Aziz; Patricia A Grady; J Randall Curtis
Journal:  J Pain Symptom Manage       Date:  2013-04-28       Impact factor: 3.612

Review 10.  Chronic pain and psychedelics: a review and proposed mechanism of action.

Authors:  Joel P Castellanos; Chris Woolley; Kelly Amanda Bruno; Fadel Zeidan; Adam Halberstadt; Timothy Furnish
Journal:  Reg Anesth Pain Med       Date:  2020-05-04       Impact factor: 6.288

View more
  1 in total

1.  The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.

Authors:  Tomas Frymann; Sophie Whitney; David B Yaden; Joshua Lipson
Journal:  Front Psychol       Date:  2022-05-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.